TEVJF Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:08):

Stats
Tagesvolumen	12.00
Durchschnittsvolumen	1 908.00
Marktkapitalisierung	13.17B
EPS	$0.0705 ( 2023-09-29 )
Nächstes Ertragsdatum	( $0 ) 2024-05-08
Last Dividend	$0.345 ( 2017-06-05 )
Next Dividend	$0 ( N/A )
P/E	-23.50
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	Fox Christine	Buy	253 968	Restricted Share Units
2023-11-20	Fox Christine	Buy	0
2023-11-15	Conway Vikki L	Buy	33 482	Restricted Share Units
2023-11-15	Bergwerk Dov	Buy	33 482	Restricted Share Units
2023-10-13	Bergwerk Dov	Sell	0	Ordinary Shares

INSIDER POWER
23.25
Last 96 transactions
Buy: 1 572 847 \| Sell: 982 807

Teva Pharmaceutical Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Teva Pharmaceutical Finanzdaten

Annual	2023
Umsatz:	$15.85B
Bruttogewinn:	$7.65B (48.25 %)
EPS:	$-0.500

FY	2023
Umsatz:	$15.85B
Bruttogewinn:	$7.65B (48.25 %)
EPS:	$-0.500

FY	2022
Umsatz:	$14.93B
Bruttogewinn:	$6.97B (46.72 %)
EPS:	$-2.19

FY	2021
Umsatz:	$15.88B
Bruttogewinn:	$7.60B (47.83 %)
EPS:	$0.380

Financial Reports:

No articles found.

Teva Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Teva Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 4.52 - low (50.11%) | Divividend Growth Potential Score: 0.653 - No dividend growth expected in the near future

Information

First Dividend	$0.346	2014-02-24
Last Dividend	$0.345	2017-06-05
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	7	--
Total Paid Out	$2.38	--
Avg. Dividend % Per Year	0.00%	--
Score	1.85	--
Div. Sustainability Score	4.52
Div.Growth Potential Score	0.653
Div. Directional Score	2.59	--

Next Divdend (Est)
(2024-07-05)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

1.85

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
WEGRY	Ex Dividend Knight	2023-10-05	Annually	0.00%
LNVGY	Ex Dividend Knight	2023-07-26	Annually	0.00%
CIBN	Ex Dividend Knight	2023-09-14	Quarterly	0.00%
SLVYY	Ex Dividend Knight	2023-05-15	Semi-Annually	0.00%
GLPEY	Ex Dividend Knight	2023-08-25	Annually	0.00%
AHCHY	Ex Dividend Junior	2023-06-01	Annually	0.00%
NCBDF	Ex Dividend Junior	2023-09-28	Annually	0.00%
CNTHP	Ex Dividend Knight	2023-07-07	Quarterly	0.00%
TDHOF	Ex Dividend Junior	2023-09-28	Annually	0.00%
HONT	Ex Dividend Junior	2023-08-14	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0374	1.500	-0.748	-1.123	[0 - 0.5]
returnOnAssetsTTM	-0.0136	1.200	-0.455	-0.546	[0 - 0.3]
returnOnEquityTTM	-0.0808	1.500	-2.01	-3.01	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.019	0.800	9.90	7.92	[1 - 3]
quickRatioTTM	0.542	0.800	-1.520	-1.216	[0.8 - 2.5]
cashRatioTTM	0.263	1.500	9.65	10.00	[0.2 - 2]
debtRatioTTM	0.464	-1.500	2.27	-3.41	[0 - 0.6]
interestCoverageTTM	0.914	1.000	-0.773	-0.773	[3 - 30]
operatingCashFlowPerShareTTM	1.220	2.00	9.59	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.751	2.00	9.62	10.00	[0 - 20]
debtEquityRatioTTM	2.68	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.482	1.000	5.29	5.29	[0.2 - 0.8]
operatingProfitMarginTTM	0.0593	1.000	-0.814	-0.814	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0679	1.000	-0.734	-0.734	[0.2 - 2]
assetTurnoverTTM	0.364	0.800	-0.904	-0.723	[0.5 - 2]
Total Score				4.52

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-22.21	1.000	-2.34	0	[1 - 100]
returnOnEquityTTM	-0.0808	2.50	-1.292	-3.01	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.751	2.00	9.75	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.220	2.00	9.59	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.256	1.500	-5.04	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0863	1.000	-0.342	0	[0.1 - 0.5]
Total Score				0.653

Teva Pharmaceutical

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Echtzeitaktualisierungen für Teva Pharmaceutical [TEVJF]

Upcoming Earnings Alert

Teva Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Commentary

Top 10 dividend Companies for OTC

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)